(Reuters) – The U.S. health regulator approved Bristol Myers Squibb’s schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side effects, the company said.
(Reporting by Puyaan Singh and Bhanvi Satija in Bengaluru and Michael Erman in New York; Editing by Krishna Chandra Eluri)
Comments